Private Equity

Bridgepoint in rude health with drug developer return

Small-cap arm of the London-based buyout firm lands a quick win with sale of Quotient Clinical

Bridgepoint in rude health with drug developer return

The small-cap arm of London-based buyout firm Bridgepoint Capital has sealed a quick and healthy return from the sale of a drugs development company it bought two years ago.

Bridgepoint Development Capital has sold Quotient Clinical to fellow London-based private equity firm GHO Capital, according to a statement on December 2.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump